Analysed GUIDED THERAPEUTICS INC (GTHP:OTCMKTS) News Sources
Guided Therapeutics Provides Updates on FDA Application Study Results, 2025 Earnings Increase and Successful Warrant Offering
31-03-2026
yahoo.com
Analysis of Guided Therapeutics' FDA Study Data Reveals Compelling Clinical Need for LuViva
17-12-2025
yahoo.com
Guided Therapeutics Receives $88,000 Payment as Third Installment of $700,000 Purchase Order with Chinese Distributor
11-12-2025
yahoo.com
Guided Therapeutics Inks Initial $200,000 Deal with New Distribution Partner Yuanshuo Medical Instruments Corporation
19-11-2025
yahoo.com
Guided Therapeutics Receives $70,000 -- Its Second of Nine Payments Totaling $700,000 -- from New Chinese Distribution Partner that Provides Products for 2 Million Annual Cervical Cancer Screenings
19-08-2025
yahoo.com
Guided Therapeutics Makes Initial Shipment to New Chinese Distribution Partner Hangzhou Dongye Medical Technology, Ltd.
02-07-2025
yahoo.com
Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor
10-06-2025
yahoo.com
What is the current price of GUIDED THERAPEUTICS INC (GTHP:OTCMKTS)?
The current price of GUIDED THERAPEUTICS INC (GTHP:OTCMKTS) is $0.2.
GUIDED THERAPEUTICS INC (GTHP:OTCMKTS) absolute price change since previous trading day?
The absolute price change of GUIDED THERAPEUTICS INC (GTHP:OTCMKTS) since the previous trading day is $0.01.
GUIDED THERAPEUTICS INC (GTHP:OTCMKTS) percentage price change since previous trading day?
The percentage price change of GUIDED THERAPEUTICS INC (GTHP:OTCMKTS) since the previous trading day is 5.2632%.
What is the most recent average sentiment score for GUIDED THERAPEUTICS INC (GTHP:OTCMKTS)?
The most recent average sentiment score for GUIDED THERAPEUTICS INC (GTHP:OTCMKTS) is 86 out of 100.
What is the most recent average sentiment for GUIDED THERAPEUTICS INC (GTHP:OTCMKTS)?
The most recent sentiment for GUIDED THERAPEUTICS INC (GTHP:OTCMKTS) is .
SEC-8K** Filing Available For GUIDED THERAPEUTICS INC (GTHP:OTCMKTS)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.